COLLAGEN DISEASES

Including

SYSTEMIC LUPUS ERYTHEMATOSUS • POLYARTERITIS

DERMATOMYOSITIS • SYSTEMIC SCLERODERMA

THROMBOTIC THROMBOCYTOPENIC PURPURA

John H. Talbott · R. Moleres Ferrandis

COLLAGEN DISEASES

——Including——

SYSTEMIC LUPUS ERYTHEMATOSUS • POLYARTERITIS

DERMATOMYOSITIS • SYSTEMIC SCLERODERMA

THROMBOTIC THROMBOCYTOPENIC PURPURA

John H. Talbott, M.D.

Professor of Medicine, The University of Buffalo School of Medicine Physician-in-Chief, Buffalo General Hospital, Buffalo, New York

and

R. Moleres Ferrandis, M.D.

Training Fellow in Arthritis of the Western New York Chapter of the Arthritis and Rheumatism Foundation



GRUNE & STRATTON NEW YORK 1956

LONDON

Copyright 1956 Grune & Stratton, Inc. 381 Fourth Avenue New York City 16

TO

Arlie V. Bock D. Bruce Dill and the late

LAWRENCE J. HENDERSON

Physician, Physiologist and Philosopher, respectively. In spite of a great difference in personality, each one was to me an outstanding individual, a fine teacher and an ever-loyal friend.

JHT

Preface

However other writers of monographs in medicine may proceed, in my own case the Preface, always prepared last, marks a pleasant cessation of labors. With more satisfaction than probably is warranted, I turn to the compilation of an index and eventually to proofreading, the culmination of twenty years of sporadic awareness of the need for a concise monograph on the disorders described herein, and the final result of eighteen months of reference work, writing and rewriting.

Twenty years of sporadic awareness refers to a brief exchange of correspondence with the late Dr. Campbell P. Howard, one-time pupil of William Osler in Baltimore, when he was Professor of Medicine in McGill University at the peak of his professional career. It was my privilege to feel the warmth of the personality of "C.P.H." only through his written words, but I can vouch for his eminence as a teacher and clinician while entrusted with the Department of Medicine at the University of Iowa, only a few miles by dirt road from my birthplace. Although the correspondence began in 1936, the origin of a common interest may be traced to the preceding year, when, at the age of sixty, Dr. Howard, upon recognizing for the first time a case of scleroderma with calcinosis, described his feelings as follows: "To a student of medicine a new clinical experience always gives a thrill. Even the most blasé hospital physician is learning something new each day though he may not be prepared to admit it; certainly at least once a month he is faced by some problem that has not confronted him before. Such was my position early in January, when on making my daily ward visit, I was

XII PREFACE

shown this patient whose case report I am about to relate; I realized that the condition was a new one to me."

The quotation above is an excerpt from the introductory paragraph to a paper presented in 1935 before the Association of American Physicians* entitled, "A Case of Early Scleroderma with Calcinosis." It should be noted also that before the same scientific assembly Dr. George Baehr presented a communication entitled, "A Diffuse Disease of the Peripheral Circulation (Usually Associated with Lupus Erythematosus and Endocarditis)." No discussion followed Dr. Howard's presentation, but several queries were addressed to Dr. Baehr. Dr. Joseph H. Pratt of Boston, inquired: "I wish Dr. Baehr would tell us if he is able to make the diagnosis of the disease [lupus] in the absence of skin lesions. If so, I am especially interested to know how he would distinguish it from rheumatoid arthritis." Several comments were made by Dr. Emanuel Libman of New York, who displayed a great interest in this communication.

Thus far in the Preface, scleroderma and lupus erythematosus have been introduced as well as the difficulty encountered at times in distinguishing lupus from rheumatoid arthritis. Dr. Howard used the term, "scleroderma with calcinosis" to describe his case, but he might have committed an error similar to mine, in describing a case of "dermatomyositis with scleroderma and calcinosis . . .,"[372] because the differentiation between dermatomyositis and scleroderma, in patients with calcinosis, has not been defined clearly. Yet one other "collagen disorder" had attracted the interest of Dr. Howard a decade earlier. He reviewed the literature on periarteritis nodosa in 1925 [216] at the same time that Moschowitz [579] described a case of thrombotic thrombocytopenic purpura.

At the time of his death in 1936 Dr. Howard had prepared a fine bibliography on the subject of calcinosis, which supplemented in some instances and duplicated in others, a similar project that I had undertaken. Only a modicum of *Transactions of the Association of American Physician, vol. 50, 1935.

PREFACE

progress could be documented before World War II brought an effective halt to my efforts. Following the war, the increasing incidence of several "rare" collagen disorders was directly responsible for the cessation of daydreaming about the preparation of the manuscript and for the stimulus to start working upon it. The results constitute the chapters that follow on Systemic Lupus Erythematosus, Polyarteritis, Dermatomyositis, Systemic Scleroderma and Thrombotic Thrombocytopenic Purpura.

It is always a pleasure to acknowledge assistance from persons and institutions who have lent a helping hand. Many times also the recipients of this acknowledgment are pleased to be so recognized. I have even assumed at times that institutions, such as hospitals and medical schools, cold impersonal structures on the outside, may derive some inward sense of appreciation when they are the object of acknowledgment.

Dr. Ricardo Ferrandis, a Castilian, studying in America and currently a Training Fellow in Arthritis, helped tremendously in the library work. Somewhat more than five times as many articles were read as are listed in the bibliography. In most instances decision regarding acceptance or rejection was made after each of us had scanned the original one or more times. But Dr. Ferrandis' work on the manuscript is not over. He has already begun to translate it into Spanish for the Latin American countries. I believe that as North Americans we are charged with the responsibility of helping, whenever we are able, to exchange suitable medical information with our associates South of the Border. I hope this, the latest of several efforts on my part to do so, will not be the last.

The pathologic material was made available by my colleagues, Drs. Kornel Terplan and Dorothy Shaver in the Department of Pathology, and Drs. Stuart Vaughan, Raymond Kibler and Miss Jeanette Corbett in the Department of Clinical Pathology. The excellence of the roentgenography is due to the interest of Dr. Gordon Culver of the Department

XIV PREFACE

of Roentgenology. Selected material for reproduction has been provided by Dr. Earl Osborne of the Department of Dermatology, by Dr. Joseph Acquilina of the Buffalo Veterans Administration Hospital, by Dr. Ashton Welsh of Cincinnati, and by Dr. Salvatore Latona of Niagara Falls.

The following physicians have provided clinical material either from their private practice or from their ward service in the hospital: Drs. Abraham H. Aaron, Carl E. Arbesman, Grovenor W. Bissell, Marvin L. Bloom, Jay I. Evans, Stephen A. Graczyk, Raymond S. Kibler, George F. Koepf, William F. Lipp, Morton H. Lipsitz, L. Maxwell Lockie, Elmer T. McGroder, Harry M. Murphy, M. Luther Musselman, Bernard M. Norcross, Francis W. O'Donnell, Howard Osgood, Harold M. Robins, Nelson G. Russell, Jr., Nelson G. Russell, Sr., Frederick T. Schnatz, Max A. Schneider, Stuart L. Vaughan, Samuel A. Vogel, Joseph E. Anderson of Olean, Alfred E. Dooley of Auburn, Walter S. Finken of Bradford, and John E. Thompson of Youngsville, Pennsylvania. Except where noted, the above-mentioned are members of the medical community of Buffalo. This is a long list, but the appreciation is conveyed individually and sincerely. I am indebted also to my secretaries, Mrs. Geri Kassirer and Miss Barbara Allan for painstaking copying. and to Mr. Raymond M. Verrill, of the English Department of Nichols School, for typereading.

I am especially grateful to Sharp & Dohme, Division of Merck & Co., for permission to reproduce the color figures and several of the black and white illustrations. The color plates (pages 1–8) appeared originally in three issues of *Seminar* in order to illustrate articles on similar subjects that were prepared prior to this manuscript. Color plates, particularly appropriate for medical reports, are prohibitive in cost. Lacking special funds, the arrangement for reproducing them would have been impossible without the aforementioned support.

Acknowledgment to institutions, as noted above, referred to essential contributions that each has made by virtue

PREFACE

of the stature enjoyed in their respective communities. A number of patients with dermatomyositis and scleroderma were followed at the Massachusetts General Hospital in the 1930's. Since 1946 the clinical material has been drawn largely from the Buffalo General Hospital. A few cases have been seen at the Veterans Administration Hospital in Buffalo, and isolated cases in other hospitals in Western New York State. Finally, the School of Medicine at the University of Buffalo has been the academic mine of precious metals from which physicians and institutions pursue their respective missions in these hills of learning, occupying varying degrees of independence, but never losing touch with the mother lode.

This monograph has been prepared without any specific grants-in-aid. However, several persons and Foundations have contributed directly to the current research program in the Department of Medicine, from which this monograph comes. I am pleased, therefore, to acknowledge financial support from the following: Mrs. Kathleen B. S. Chard, Cazenovia, New York; Mr. Alton Wood, Eden, New York; The National Institutes of Health, Bethesda, Maryland; The John A. Hartford Foundation, New York City; The Western New York Chapter of the Arthritis and Rheumatism Foundation; and the Masonic Foundation for Medical Research and Human Welfare.

JHT

Eden, New York July, 1955

COLOR PLATES

SYSTEMIC LUPUS E	RY'	THI	EM.	AT	OU	S		
PLATE I (see text, page 17).				,				1
PLATE II (see text, page 35).			200					1
PLATE III (see text, page 38)								
PLATE IV (see text, page 62)								2
Plate V (see text, page 63).								3
POLYARTE	RIT	TIS						
PLATE VI (see text, page 85)							,	3
PLATE VII (see text, page 85)								
Plate VIII (see text, page 85)				,		÷		4
DERMATOM	YOS	SIT	IS					
PLATE IX (see text, page 112)								5
PLATE X (see text, page 123)								
Plate XI (see text, page 123)								
SYSTEMIC SCLI	ERO	DE	RIV	IΑ				
PLATE XII (see text, page 137)								6
PLATE XIII (see text, page 137)								
PLATE XIV (see text, page 146								
Plate XV (see text, page 147)								
THROMBOTIC THROMBOC	ΥT	OP:	EN]	[C	PU.	RPI	JRA	4
PLATE XVI (see text page 185))							5

Contents

Preface .	:														xi
COLOR PLAT	ES														1
Introduction	N														9
SY	STE	EMI	СІ	UF	US	E	RYT	HF	MA	ATO	SU	IS.	17		
															18
INCIDENCE															20
RELATION TO	o Oa	THEF	R Co	DLL	AGE	ΝI)ISO	RDE	RS						22
ETIOLOGY AN	ND F	ATH	OGI	ENE	SIS										26
PATHOLOGY															30
Connect	tive	Tiss	sue												31
Vascula	r Le	esior	1S												32
Skin .															34
Kidneys														,	35
Heart															36
Lungs			×	,											38
Spleen															38
Involve	men	t of	Ot	her	Sy	ster	ns								39
CLINICAL FI	NDI	NGS													43
Skin.															44
Joints a:	nd N	Muse	cles	,											45
Heart a															47
Lungs															48
Gastroin	ites	tinal	Tr	act											52
Liver, I															52
Genitou															53
Central	and	l Pe	ripl	iera	al N	Verv	ous	Sy	ster	ns					54
Eyes															56
LABORATORY	FIN	IDIN	GS												57
Red Ble	boc	Cel	ls				,								57
White I	Bloo	d Ce	ells												58
Platelet	S														58
Plasma	Pro	otein	IS												59

VIII	CONTENTS

The LE Cell and the LE Rosette Phenomenon 62 DIAGNOSIS 65 CLINICAL COURSE 666 TREATMENT 68 POLYARTERITIS, 74 HISTORICAL 75 INCIDENCE 77 RELATION TO OTHER COLLAGEN DISORDERS 78 ETIOLOGY AND PATHOGENESIS 79 PATHOLOGY 84 CLINICAL FINDINGS 86 Kidneys 88 Heart 89 Gastrointestinal System 90 Lungs 92 Central and Peripheral Nervous Systems 97 Eyes 99 Muscles and Joints 100 Skin 101 Endocrine Glands 102 LABORATORY FINDINGS 103 DIAGNOSIS 105 CLINICAL COURSE 107 TREATMENT 108 DERMATOMYOSITIS, 112 HISTORICAL 119 ETIOLOGY AND PATHOGENESIS 119 ETIOLOGY 122 CLINICAL FINDINGS 112 NEOPLASTIC DISEASE AND DERMATOMYOSITIS 119 ETIOLOGY AND PATHOGENESIS 121 PATHOLOGY 122 CLINICAL FINDINGS 125 LABORATORY FINDINGS	Serologic Tests for	Syj	phil	is								60
CLINICAL COURSE 66 TREATMENT 68 POLYARTERITIS, 74 HISTORICAL 75 INCIDENCE 77 RELATION TO OTHER COLLAGEN DISORDERS 78 ETIOLOGY AND PATHOGENESIS 79 PATHOLOGY 84 CLINICAL FINDINGS 86 Kidneys 88 Heart 89 Gastrointestinal System 90 Lungs 92 Central and Peripheral Nervous Systems 97 Eyes 99 Muscles and Joints 100 Skin 101 Endocrine Glands 102 Laboratory Findings 103 DIAGNOSIS 103 CLINICAL Course 107 Treatment 108 DERMATOMYOSITIS, 112 Historical 112 Incidence 114 Relation to Other Collagen Disorders 115 Neoplastic Disease and Dermatomyositis 119 Etiology and Pathogenesis 121 <	The LE Cell and th	ie I	E	Rose	tte	Phe	nor	nen	on			62
CLINICAL COURSE												65
POLYARTERITIS, 74 Historical	CLINICAL COURSE .				,							66
Historical	Treatment											68
Historical	PO)LY	YAF	RTE	RIT	TIS.	74					
Incidence												75
RELATION TO OTHER COLLAGEN DISORDERS 78 ETIOLOGY AND PATHOGENESIS 79 PATHOLOGY 84 CLINICAL FINDINGS 86 Kidneys 88 Heart 89 Gastrointestinal System 90 Lungs 92 Central and Peripheral Nervous Systems 97 Eyes 99 Muscles and Joints 100 Skin 101 Endocrine Glands 102 LABORATORY FINDINGS 103 DIAGNOSIS 105 CLINICAL COURSE 107 TREATMENT 108 DERMATOMYOSITIS, 112 HISTORICAL 112 INCIDIENCE 114 RELATION TO OTHER COLLAGEN DISORDERS 115 NEOPLASTIC DISEASE AND DERMATOMYOSITIS 119 ETIOLOGY AND PATHOGENESIS 121 PATHOLOGY 122 CLINICAL FINDINGS 125 LABORATORY FINDINGS 125 LABORATORY FINDINGS 129 DIAGNOSIS 132 CLINICAL COURSE 134												
ETIOLOGY AND PATHOGENESIS 79 PATHOLOGY 84 CLINICAL FINDINGS 86 Kidneys 88 Heart 89 Gastrointestinal System 90 Lungs 92 Central and Peripheral Nervous Systems 97 Eyes 99 Muscles and Joints 100 Skin 101 Endocrine Glands 102 Laboratory Findings 103 Diagnosis 105 Clinical Course 107 Treatment 108 DERMATOMYOSITIS, 112 Historical 114 Relation to Other Collagen Disorders 115 Neoplastic Disease and Dermatomyositis 115 Neoplastic Disease and Dermatomyositis 119 Etiology and Pathogenesis 121 Pathology 122 Clinical Findings 125 Laboratory Findings 125 Laboratory Findings 129 Diagnosis 134 Treatment 136 SYSTEMIC SCLERODERMA, 137 <td></td>												
PATHOLOGY 84 CLINICAL FINDINGS 86 Kidneys 88 Heart 89 Gastrointestinal System 90 Lungs 92 Central and Peripheral Nervous Systems 97 Eyes 99 Muscles and Joints 100 Skin 101 Endocrine Glands 102 LABORATORY FINDINGS 103 DIAGNOSIS 105 CLINICAL COURSE 107 TREATMENT 108 DERMATOMYOSITIS, 112 HISTORICAL 112 INCIDIENCE 114 RELATION TO OTHER COLLAGEN DISORDERS 115 NEOPLASTIC DISEASE AND DERMATOMYOSITIS 119 ETIOLOGY AND PATHOGENESIS 121 PATHOLOGY 122 CLINICAL FINDINGS 125 LABORATORY FINDINGS 129 DIAGNOSIS 132 CLINICAL COURSE 134 TREATMENT 136 SYSTEMIC SCLERODERMA, 137												
CLINICAL FINDINGS 86 Kidneys 88 Heart 89 Gastrointestinal System 90 Lungs 92 Central and Peripheral Nervous Systems 97 Eyes 99 Muscles and Joints 100 Skin 101 Endocrine Glands 102 Laboratory Findings 103 Diagnosis 105 Clinical Course 107 Treatment 108 DERMATOMYOSITIS, 112 Historical 112 Incidence 114 Relation to Other Collagen Disorders 115 Neoplastic Disease and Dermatomyositis 119 Etiology and Pathogenesis 121 Pathology 122 Clinical Findings 125 Laboratory Findings 125 Laboratory Findings 125 Laboratory Findings 129 Diagnosis 132 Clinical Course 134 Treatment 135 SYSTEMIC SCLERODERMA, 137												
Kidneys 88 Heart 89 Gastrointestinal System 90 Lungs 92 Central and Peripheral Nervous Systems 97 Eyes 99 Muscles and Joints 100 Skin 101 Endocrine Glands 102 Laboratory Findings 103 Diagnosis 105 Clinical Course 107 Treatment 108 DERMATOMYOSITIS, 112 Historical 112 Incidence 114 Relation to Other Collagen Disorders 115 Neoplastic Disease and Dermatomyositis 119 Etiology and Pathogenesis 121 Pathology 122 Clinical Findings 125 Laboratory Findings 129 Diagnosis 134 Clinical Course 134 Treatment 135 SYSTEMIC SCLERODERMA, 137	CLINICAL FINDINGS											
Heart 89 Gastrointestinal System 90 Lungs 92 Central and Peripheral Nervous Systems 97 Eyes 99 Muscles and Joints 100 Skin 101 Endocrine Glands 102 Laboratory Findings 103 Diagnosis 105 Clinical Course 107 Treatment 108 DERMATOMYOSITIS, 112 Historical 112 Incidence 114 Relation to Other Collagen Disorders 115 Neoplastic Disease and Dermatomyositis 119 Etiology and Pathogenesis 121 Pathology 122 Clinical Findings 125 Laboratory Findings 129 Diagnosis 132 Clinical Course 134 Treatment 135 SYSTEMIC SCLERODERMA, 137												_
Gastrointestinal System 90 Lungs 92 Central and Peripheral Nervous Systems 97 Eyes 99 Muscles and Joints 100 Skin 101 Endocrine Glands 102 Laboratory Findings 103 Diagnosis 105 Clinical Course 107 Treatment 108 DERMATOMYOSITIS, 112 Historical 112 Incidence 114 Relation to Other Collagen Disorders 115 Neoplastic Disease and Dermatomyositis 119 Etiology and Pathogenesis 121 Pathology 122 Clinical Findings 125 Laboratory Findings 125 Laboratory Findings 129 Diagnosis 132 Clinical Course 134 Treatment 135 SYSTEMIC SCLERODERMA, 137	Heart											
Lungs 92 Central and Peripheral Nervous Systems 97 Eyes 99 Muscles and Joints 100 Skin 101 Endocrine Glands 102 Laboratory Findings 103 Diagnosis 105 Clinical Course 107 Treatment 108 DERMATOMYOSITIS, 112 Historical 112 Incidence 114 Relation to Other Collagen Disorders 115 Neoplastic Disease and Dermatomyositis 119 Etiology and Pathogenesis 121 Pathology 122 Clinical Findings 125 Laboratory Findings 129 Diagnosis 132 Clinical Course 134 Treatment 135 SYSTEMIC SCLERODERMA, 137												
Central and Peripheral Nervous Systems 97 Eyes												
Eyes 99 Muscles and Joints 100 Skin 101 Endocrine Glands 102 Laboratory Findings 103 Diagnosis 105 Clinical Course 107 Treatment 108 DERMATOMYOSITIS, 112 Historical 112 Incidence 114 Relation to Other Collagen Disorders 115 Neoplastic Disease and Dermatomyositis 119 Etiology and Pathogenesis 121 Pathology 122 Clinical Findings 125 Laboratory Findings 129 Diagnosis 132 Clinical Course 134 Treatment 135 SYSTEMIC SCLERODERMA, 137	Control and Parink	oro	1 N	Jorga		STE	ton	10				_
Muscles and Joints 100 Skin 101 Endocrine Glands 102 Laboratory Findings 103 Diagnosis 105 Clinical Course 107 Treatment 108 DERMATOMYOSITIS, 112 Historical 112 Incidence 114 Relation to Other Collagen Disorders 115 Neoplastic Disease and Dermatomyositis 119 Etiology and Pathogenesis 121 Pathology 122 Clinical Findings 125 Laboratory Findings 129 Diagnosis 132 Clinical Course 134 Treatment 135 SYSTEMIC SCLERODERMA, 137												
Skin 101 Endocrine Glands 102 Laboratory Findings 103 Diagnosis 105 Clinical Course 107 Treatment 108 DERMATOMYOSITIS, 112 Historical 112 Incidence 114 Relation to Other Collagen Disorders 115 Neoplastic Disease and Dermatomyositis 119 Etiology and Pathogenesis 121 Pathology 122 Clinical Findings 125 Laboratory Findings 129 Diagnosis 132 Clinical Course 134 Treatment 135 SYSTEMIC SCLERODERMA, 137												
Endocrine Glands 102 Laboratory Findings 103 Diagnosis 105 Clinical Course 107 Treatment 108 DERMATOMYOSITIS, 112 Historical 112 Incidence 114 Relation to Other Collagen Disorders 115 Neoplastic Disease and Dermatomyositis 119 Etiology and Pathogenesis 121 Pathology 122 Clinical Findings 125 Laboratory Findings 129 Diagnosis 132 Clinical Course 134 Treatment 135 SYSTEMIC SCLERODERMA, 137												
Laboratory Findings 103 Diagnosis 105 Clinical Course 107 Treatment 108 DERMATOMYOSITIS, 112 Historical 112 Incidence 114 Relation to Other Collagen Disorders 115 Neoplastic Disease and Dermatomyositis 119 Etiology and Pathogenesis 121 Pathology 122 Clinical Findings 125 Laboratory Findings 129 Diagnosis 132 Clinical Course 134 Treatment 135 SYSTEMIC SCLERODERMA, 137	Endonina Clanda											
DIAGNOSIS 105 CLINICAL COURSE 107 TREATMENT 108 DERMATOMYOSITIS, 112 HISTORICAL 112 INCIDENCE 114 RELATION TO OTHER COLLAGEN DISORDERS 115 NEOPLASTIC DISEASE AND DERMATOMYOSITIS 119 ETIOLOGY AND PATHOGENESIS 121 PATHOLOGY 122 CLINICAL FINDINGS 125 LABORATORY FINDINGS 129 DIAGNOSIS 132 CLINICAL COURSE 134 TREATMENT 135 SYSTEMIC SCLERODERMA, 137												
CLINICAL COURSE 107 TREATMENT 108 DERMATOMYOSITIS, 112 HISTORICAL 112 INCIDENCE 114 RELATION TO OTHER COLLAGEN DISORDERS 115 NEOPLASTIC DISEASE AND DERMATOMYOSITIS 119 ETIOLOGY AND PATHOGENESIS 121 PATHOLOGY 122 CLINICAL FINDINGS 125 LABORATORY FINDINGS 129 DIAGNOSIS 134 TREATMENT 135 SYSTEMIC SCLERODERMA, 137												
TREATMENT 108 DERMATOMYOSITIS, 112 Historical 112 Incidence 114 Relation to Other Collagen Disorders 115 Neoplastic Disease and Dermatomyositis 119 Etiology and Pathogenesis 121 Pathology 122 Clinical Findings 125 Laboratory Findings 129 Diagnosis 132 Clinical Course 134 Treatment 135 SYSTEMIC SCLERODERMA, 137												200
DERMATOMYOSITIS, 112												
Historical	I REATMENT	*	٠			٠			٠		•	108
INCIDENCE												
Relation to Other Collagen Disorders												112
Neoplastic Disease and Dermatomyositis 119 Etiology and Pathogenesis 121 Pathology 122 Clinical Findings 125 Laboratory Findings 129 Diagnosis 132 Clinical Course 134 Treatment 135 SYSTEMIC SCLERODERMA, 137												
Etiology and Pathogenesis 121												115
PATHOLOGY 122 CLINICAL FINDINGS 125 LABORATORY FINDINGS 129 DIAGNOSIS 132 CLINICAL COURSE 134 TREATMENT SYSTEMIC SCLERODERMA, 137	NEOPLASTIC DISEASE AN	D I)ER	MAT	OM	YOSI	TIS					119
CLINICAL FINDINGS												121
Laboratory Findings	Pathology											122
DIAGNOSIS	CLINICAL FINDINGS .											125
CLINICAL COURSE	LABORATORY FINDINGS											129
CLINICAL COURSE	Diagnosis											132
SYSTEMIC SCLERODERMA, 137												134
	Treatment											135
	SYSTEN	AIC.	SO	OLE:	RO1	DEF	RM	Α. 1	137			
												138
Incidence	and the second s											

CONTENTS														IX
RELATION TO	Отне	r C	OLL	AGE	n D	ISOI	RDEI	RS						141
ETIOLOGY AND	PAT	HOG	ENE	SIS										142
PATHOLOGY														146
CLINICAL FIN	DINGS													150
LABORATORY 3	Findii	NGS												155
Diagnosis										,				174
CLINICAL CO	URSE													175
TREATMENT														176
THROMBO	OTIC	ТН	RO	MB	OC	YTO	PE	NIC	P	URI	PUF	RA,	18	1
														182
Incidence														183
RELATION TO														183
ETIOLOGY AND	PAT	HOG	ENE	SIS			,							184
PATHOLOGY														185
CLINICAL FIN	DINGS													186
LABORATORY 3	Findii	NGS												187
Diagnosis											-			189
CLINICAL CO														190
Treatment														191
Bibliography														192
Systemic	Lupi	is E	rytl	nem	atos	sus								192
Polyarte														202
Dermato														211
Systemic														215
Thrombo														223
INDEX .														226



PLATE I.—Butterfly rash on the face of a patient with SLE.




Plate II.—Section of a kidney from a patient who died from SLE. There is proliferation of endothelial cells of the glomerular capillaries and hyaline thickening of the basement membrane which creates the "wire-loop" appearance. \times 96.





PLATE III.—Section of the epicardium from a patient who died from SLE. The epicardium is thickened with fibrinoid degeneration surrounding the vein. Masson Trichrome stain. \times 96.



 $P_{\rm LATE}$ IV.—LE cells in the buffy coat of a patient with SLE. Wright's stain. \times 1000.




Plate V.—LE rosettes in the buffy coat of a patient with SLE. Wright's stain. \times 450.




PLATE VI.—Section of a muscle removed at biopsy from a patient with polyarteritis. There is acute fibrinoid necrosis of the media in an arteriole surrounded by dense cellular infiltration. The inflammation extends between the adjoining muscle bundles. \times 96.




PLATE VII.—Section of a muscle from a patient who died from polyarteritis. There is a small aneurysmal bulge of the artery with chronic changes. These consist of eccentric endarteritic proliferation and fibrosis with scattered round cell infiltration in the adventitia. \times 96.




PLATE VIII.—Section of a muscle from a patient who died from polyarteritis. Chronic changes in the arterioles consist of irregular narrowing of the lumen, fibrosis of the intima and extensive fibrosis of the adventitia. Except for a small segment, the media is well preserved. × 96.